Discover Cabaletta Bio's promising CAR T-cell therapy for autoimmune diseases! Durable efficacy, FDA support, and clinical potential make this attractive.

"We have identified a group of patients with a necrotizing myopathy and a novel anti-200/100 autoantibody specificity," said Dr. Andrew Mammen, M.D., Ph.D., and lead author of the study.

Necrotizing myopathy: muscle weakness. Polymyalgia rheumatica occurs more commonly in older persons and preferentially affects the proximal muscles with markedly elevated measures of inflammation ...

Title: Correlative Studies of CABA-201 in Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus Date and Time: November 16, 2024, 10:30 a.m. – 12:30 p.m. ET ...

Financially, the company reported cash and cash equivalents of $131.8 million as of March 31, 2025, down from $164.0 million at the end of 2024.

This may be due to unmasking an underlying condition (e.g., polymyositis, dermatomyositis, or necrotizing myopathy). Some of these patients will have anti-HMG CoA reductase antibodies.

A memorial benefit for Jon Peterson will be held from 11 a.m. to 2 p.m. Sunday, Oct. 20, at Labby's, 1100 19th Ave. N., Fargo. Proceeds from the free-will lunch, silent, online, and live auctions ...

Five of the main subtypes include dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, polymyositis, and overlap myositis, all of which can lead to significant ...

On December 13th, Gregory Charles Harrass entered his eternal rest following an eight year long battle against necrotizing myopathy and cirrhosis of the liver. He is survived by the love of his ...

Myositis in general affects 50,000 to 75,000 people in the U.S., but the statin-triggered type Furlan had — called HMGCR necrotizing myopathy — is seen in only two or three out of 100,000 ...

Idiopathic myopathies include polymyositis, dermatomyositis, non-specific myositis, and necrotizing myopathy. 1 These are very rare conditions and may be missed if one is unfamiliar with the ...

REDWOOD CITY, Calif. & BOSTON, October 16, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...